All News

Found 65,177 articles

• Chimerix Appoints Allen Melemed, M.D. as Chief Medical OfficerFormer Eli Lilly Veteran Brings Deep Oncology Clinical and Regulatory Expertise

  6/22/2020

  Chimerix, a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced the appointment of Allen Melemed, M.D., M.B.A., as Chief Medical Officer.

• HOOKIPA Announces Positive Phase 2 Interim Safety and Immunogenicity Results for its CMV Vaccine Candidate HB‑101

  6/22/2020

  HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, announced positive interim results on its prophylactic Cytomegalovirus vaccine candidate HB‑101.

• FibroGen Appoints Thane Wettig as Chief Commercial Officer

  6/22/2020

  FibroGen, Inc. announced the appointment of Thane Wettig to the newly-created position of Chief Commercial Officer, where he will lead FibroGen’s commercialization efforts, leveraging more than 30 years of global biopharmaceutical leadership and experience.

• Altimmune Announces IND Clearance for a Phase 2 Trial of HepTcell™ Immunotherapeutic for the Treatment of Chronic Hepatitis B

  6/22/2020

  Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application to conduct a Phase 2 trial of HepTcell, a peptide-based immunotherapeutic for the treatment of chronic hepatitis B.

• Lantheus Completes Merger with Progenics

  6/22/2020

  Lantheus Holdings, Inc. announced that it has completed its previously announced merger with Progenics Pharmaceuticals, Inc., an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer.

• AGTC Announces Significant Productivity and Quality Enhancement To Its Proprietary Manufacturing Process

  6/22/2020

  Upgraded Manufacturing Process Being Used For Production Of Pivotal Stage Clinical Trial Materials

• Pfizer Announces Start of Four Phase 3 Clinical Trials for Investigational Vaccines

  6/22/2020

  First subjects recently administered immunizations in two studies of 20-valent pneumococcal conjugate vaccine candidate in infants; a pentavalent meningococcal vaccine candidate in adolescents; and a respiratory syncytial virus vaccine candidate in pregnant women

• Deciphera Announces Health Canada’s Authorization of QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor

  6/22/2020

  QINLOCK Significantly Improved Progression-Free Survival and Showed Clinically Meaningful Overall Survival in Global INVICTUS Phase 3 Study

• Bicycle Therapeutics Presents New Translational Data for BT5528 and Preclinical Data for Tumor-targeted Immune Cell Agonists at AACR Virtual Annual Meeting II

  6/22/2020

  Bicycle Therapeutics plc announced that new translational data for BT5528 and preclinical data for tumor-targeted immune cell agonists will be presented during poster sessions at the American Association for Cancer Research Virtual Annual Meeting II on June 22-24, 2020.

• Merck Announces That V114, Its Investigational 15-valent Pneumococcal Conjugate Vaccine, Met Safety and Immunogenicity Objectives in Initial Phase 3 Studies in Adults

  6/22/2020

  Merck, known as MSD outside the United States and Canada, announced results from two initial Phase 3 studies evaluating the safety, tolerability and immunogenicity of V114, the company’s investigational 15-valent pneumococcal conjugate vaccine.

• Tarsius Pharma Completes Patient Enrollment in Clinical Trial of TRS01 in Patients With Non-infectious Uveitis

  6/22/2020

  Tarsius Pharma , a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for treatment of ocular inflammation, today announced the completion of patient enrollment in the company's Phase I/II trial of TRS01 in patients with active anterior non-infectious uveitis.

• Seres Therapeutics Appoints Terri Young, Ph.D., R.Ph., Experienced Commercial Leader, as Executive Vice President, Chief Commercial and Strategy Officer

  6/22/2020

  Dr. Young to strengthen commercial expertise ahead of SER-109 Phase 3 data readout, and to maximize the potential of Seres’ microbiome therapeutic pipeline

• Merck’s KEYTRUDA® (pembrolizumab) Approved in China for Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Whose Tumors Express PD-L1 (CPS ≥10)

  6/22/2020

  KEYTRUDA Is Now Approved Across Five indications for Three Different Types of Cancer in China and Is First Anti-PD-1 Therapy Approved for Esophageal Cancer

• Immunic, Inc. to Join Russell 3000® Index

  6/22/2020

  Immunic, Inc. announced that the company is set to join the broad-market Russell 3000® Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the US market opens on June 29, according to a final list of additions accessed on June 19.

• Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology

  6/22/2020

  Combination to bring germline and somatic testing, liquid biopsy and tissue genomic profiling onto a single platform to offer patients a full suite of cancer testing for risk, therapy optimization and personalized cancer monitoring

• Revolution Medicines Announces Dosing of First Patient in Clinical Study of RMC-4630 (SAR442720) Combined with PD-1 InhibitorCombination of Investigational SHP2 Inhibitor and Anti-PD-1 Antibody to be Evaluated in Patients with Solid Tumors

  6/22/2020

  Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today announced dosing of the first patient in a multicenter Phase 1 clinical trial evaluating the combination of RMC-4630 (SAR442720), the company’s investigational SHP2 inhibitor, and pembrolizumab (Keytruda ® ), an anti-PD-1 antibody. The trial, which is being sponsored and conducted

• BIOLASE, Inc. Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering

  6/22/2020

  Certain members of Biolase's executive management and directors have indicated their intent to subscribe to the rights offering

• Soligenix to Join Russell Microcap® Index

  6/22/2020

  Soligenix, Inc. announced that the Company is set to join the Russell Microcap® Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the US market opens on June 29th, according to a final list of additions posted June 15th.

• FSD Pharma Reports Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultramicronized PEA

  6/22/2020

  FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (“FSD Pharma” or the "Company") today announced favorable topline results from its Phase 1 randomized, double-blind, placebo-controlled study of ultramicronized palmitoylethanolamide (PEA), or FSD201. This single-site study was conducted at the Alf

• SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and GlaxoSmithKline’s Belantamab Mafodotin for the Treatment of Relapsed or Refractory Multiple Myeloma

  6/22/2020

  SpringWorks Therapeutics, Inc. announced that the first patient has been dosed in a Phase 1b clinical trial evaluating SpringWorks Therapeutics’ investigational gamma secretase inhibitor, nirogacestat, in combination with GlaxoSmithKline’s investigational anti-B-cell maturation antigen antibody-drug conjugate, belantamab mafodotin, in patients with relapsed or refractory multiple myeloma.